New dedicated biopharma event launches alongside CPhI Worldwide 2018 in Madrid26 Oct 2017
New event to create unique synergies between the parallel worlds of large, small molecules and contract services.
UBM’s pharma portfolio announces the launch of a new bespoke and independently branded biopharma event, BioLive, next year in Madrid (9-11 October 2018 at IFEMA, Feria de Madrid) – specifically for bioprocessing and manufacturing.
The new event has been created after independent research identified a gap in the market for a new global exhibition and content platform that could establish premium-class, global leadership across the entire bio manufacturing value chain.
BioLive will serve as a global hub for both upstream and downstream processing and manufacturing, connecting biotechs, Big Pharma and service providers including CDMOs and CROs from early-stage development to commercial manufacturing and regulatory services. It will also feature biogeneric and bioinnovator audiences through to manufacturing and laboratory specialists.
Analyst research indicated that running the new event in parallel to its enormous contract services (ICSE) and small molecule (CPhI Worldwide) exhibitions – both currently the world’s largest in their respective areas – would create natural synergies and establish the first truly global hub covering the entire biopharma and pharma supply chains.
“It’s a hugely exciting time for the bio industry globally and we expect rapid growth in what is now a maturing supply chain. Independent research showed a dissatisfaction amongst existing options, and we have identified that we can provide broader depth in bio manufacturing and processing, whilst capitalising on our collective portfolio strength to bring additional value by combining the small and large molecule worlds together with contract services,” commented Rutger Oudejans, Brand Director at UBM. He added, “It is firstly to provide an ecosystem to bring together the bio development and manufacturing sectors. But it also enables companies and professionals involved across the full pharma value chain of both small and large molecule to learn from each other and evolve new strategies to overcome the challenges in bio processing and manufacturing.”
Attendees at BioLive will benefit from a mixture of science and technology content - including presentations and conferences on the latest bio innovations and techniques – alongside specialised business development and partnering programmes to help them directly match with the most appropriate partners.
BioLive will help big pharma’s bio divisions and biopharma giants to assess the specific niche services they need, such as analytics and testing. Conversely, the event will empower the small- and medium-sized bio innovators who want to feed new therapies into the development pipelines of larger companies. Bio innovators will also be able to look for the external partners they need to push forward their drug development and commercialization programmes.
In addition, BioLive will include the producers of specialized bio lab equipment – such as high-performance liquid chromatography – needed for biopharmaceutical research, QC and regulatory submissions. Alongside the plethora of adjacent industries from reagent suppliers, CROs to equipment, consultancy and service providers from across the whole bio value chain.
There is great potential in bringing the bio community together under the auspices of one new global event – running at the same time as CPhI Worldwide. The launch of BioLive will help accelerate the development of the bio supply chain, improve knowledge exchange, and create a more collaborative bio/pharma environment.
Eric Langer, President and Managing Partner, BioPlan Associates added his support to events that facilitate collaboration, commenting: “This event has been developed to provide an opportunity for both bio and pharma executives to meet and exchange ideas, and to address key challenges the industry faces, including how to overcome supply chain, processing and manufacturing challenges. The industry needs an effective forum where it can centralize both bio and pharma partners who can now meet different parts of the global bio/pharma industry, especially as the bio manufacturing segment matures. Industry data suggests that biopharma can still learn much from small molecule pharma, and that is why this new event could provide unique perspectives that can advance the bio industry.”
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market
9 Sep 2019
Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.Read more
Take part in pharma’s largest reputation survey
6 Sep 2019
Use your voice to shape CPhI Worldwide's third annual global survey of the major trends, changes and developments in the industry.Read more
Meet Avivia / Excipia at booth B56 Hall 12.1 CPhI Frankfurt 2019
29 Aug 2019
Meet Avivia at booth B56 Hall 12.1 CPhI Frankfurt 2019Read more
Switzerland overtakes Germany as Europe’s biggest drug delivery innovator
16 Aug 2019
Pipeline of new drugs has helped drive increased innovation in packaging and drug delivery devices.Read more
Growing domestic manufacturing creates new opportunities for international pharma in the Middle East
5 Aug 2019
Opportunities abound at CPhI MEA and experts anticipate regional generic companies acting as CMOs for international companies looking to enter the region.Read more
Drive for generics sees Korea increasingly attractive to international pharma
31 Jul 2019
Korean companies are opening more facilities overseas and using CPhI Korea to look for new international partners.Read more
Huge CPhI & P-MEC China a direct result of surging manufacturing
22 Jul 2019
Great Hall of China: Informa adds additional capacity to Asia’s largest pharma event with record 66,000+ visits from 141 countries.Read more
Fresh data on protein interactions in Alzheimer’s disease
2 Jul 2019
Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.Read more
Piramal expands its high potency API capability
25 Jun 2019
Becomes one of only a few companies in the contract development and manufacturing market that can produce HPAPIs at such low OELs.Read more
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products
18 Jun 2019
Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation